 |
|||||||||
 |
|||||||||
February 1, 2023 – TheNewswire – Cybin (NYSEAMEX: CYBN), a biopharmaceutical company focused on advancing psychedelics to therapies, has received approval for first-in-human dosing of its proprietary molecule CYB004. This marks a major milestone as it is the first time a deuterated N,N-dimethyltryptamine (DMT) molecule will be evaluated in humans.
The Phase 1 trial, which the company says represents the largest ever DMT trial, is being conducted in the Netherlands. Preclinical studies have shown improved bioavailability and a longer duration of effect compared to DMT, offering the potential for more convenient dosing methods. Cybin has secured a U.S. patent for its proprietary molecule, which it says provides protection until 2041.
The Company says that it plans to conduct further evaluations for the treatment of generalized anxiety disorder with or without major depressive disorder.
Doug Drysdale, Cybin’s Chief Executive Officer stated: “The ability to evaluate our novel CYB molecule in humans at this early stage is a significant achievement in clinical development and will provide important insight into the pharmacokinetic and pharmacodynamic properties of CYB004 in addition to what we have already learned through our study of DMT.”
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.
Shares of Cybin trade on the NYSE under the ticker symbol CYBN. For more information visit www.greenstocknews.com
Disclaimer
This content is not financial advice and is for information, education and entertainment purposes only. Green Stock News is not responsible for any losses related to the financial decisions made by you. Video content and other materials including web content are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Green Stock News is not responsible for any gains or losses that result from the opinions expressed in this video or materials that it publishes electronically.
View original video news clips here: https://greenstocknews.com/green-stock-newswire
Copyright (c) 2023 TheNewswire – All rights reserved.